Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A TRIAL OF BUSPIRONE FOR THE CONTROL OF DISRUPTIVE BEHAVIORS IN COMMUNITY-DWELLING PATIENTS WITH DEMENTIA
Autore:
LEVY MA; BURGIO LD; SWEET R; BONINO P; JANOSKY J; PEREL J;
Indirizzi:
UNIV MASSACHUSETTS,MED CTR CENT MASSACHUSETTS,DEPT MED,DIV GERIATR PRIMARY CARE WORCESTER MA 01605 UNIV ALABAMA,DEPT MED BIRMINGHAM AL 35294 UNIV PITTSBURGH,DEPT PSYCHIAT PITTSBURGH PA 15260 UNIV PITTSBURGH,DEPT MED PITTSBURGH PA 15260 UNIV PITTSBURGH,DEPT COMMUNITY MED PITTSBURGH PA 15260
Titolo Testata:
International journal of geriatric psychiatry
fascicolo: 10, volume: 9, anno: 1994,
pagine: 841 - 848
SICI:
0885-6230(1994)9:10<841:ATOBFT>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
PSYCHOTROPIC-DRUG USE; PSYCHOACTIVE MEDICATION; ALZHEIMERS-DISEASE; ELDERLY SUBJECTS; CARE FACILITY; NURSING-HOME; PHARMACOKINETICS; AGGRESSION; RELATIVES; PLACEBO;
Keywords:
DEMENTIA; BUSPIRONE; AGITATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social Sciences Citation Index
Social Sciences Citation Index
Citazioni:
45
Recensione:
Indirizzi per estratti:
Citazione:
M.A. Levy et al., "A TRIAL OF BUSPIRONE FOR THE CONTROL OF DISRUPTIVE BEHAVIORS IN COMMUNITY-DWELLING PATIENTS WITH DEMENTIA", International journal of geriatric psychiatry, 9(10), 1994, pp. 841-848

Abstract

We report the results of a pilot study examining the dose-response ofbuspirone for the treatment of agitated and disruptive behaviors in dementia patients. Patients were identified by physician referral, chart review and caregiver response to newspaper advertisements. All subjects met NINCDS-ADRDA criteria for probable Alzheimer's disease. Twentysubjects were entered into the study, 12 completed the protocol. After a washout period, all subjects received 1 week of placebo followed by approximately 2 weeks each of buspirone 15 mg, 30 mg, 45 mg and 60 mg daily. The primary outcome measure was the total score on Reisberg'sBehavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD),which was administered at baseline, the end of the placebo phase and at the end of each dosage interval. Significant improvement in the mean score was seen at a daily dosage of 30 mg (p <X0.05 vs placebo). Significant improvement was also seen on the delusion, aggression and anxiety subscales of the BEHAVE-AD. Few side-effects were noted. These data suggest that the optimal starting dosage of buspirone for the treatment of behavioral pathology in dementia patients is 30 mg daily. Individual patients may have their best response at dosages ranging from 15 to 60 mg daily. Confirmation of these findings requires a double-blind, placebo-controlled clinical trail.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 06:11:15